AVNS Stock Cash Flow Statements

Avanos Medical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Avanos Medical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31

operating activities
net income	-76,800,000	6,600,000	-397,300,000	4,300,000	1,800,000	-900,000	10,500,000	-3,700,000	-68,100,000	-500,000	16,900,000	16,400,000	11,400,000	5,800,000	10,000,000	-35,100,000	37,900,000	-7,600,000	-47,200,000	19,300,000	-3,000,000	3,700,000	-6,100,000	-11,500,000	-8,000,000	-20,300,000	-2,200,000	4,200,000	35,300,000	20,200,000	32,800,000	16,600,000	17,100,000	12,800,000	10,000,000	9,100,000	6,500,000	14,200,000	14,500,000	-470,500,000	8,000,000	21,700,000	-2,400,000
depreciation and amortization	10,000,000	9,600,000	11,100,000	11,700,000	11,300,000	11,400,000	11,500,000	11,000,000	11,500,000	12,100,000	13,400,000	11,600,000	11,600,000	11,100,000	9,500,000	9,600,000	9,500,000	9,700,000	10,800,000	10,700,000	10,800,000	10,600,000	11,300,000	8,700,000	8,500,000	8,400,000	9,000,000	8,900,000	7,800,000	7,800,000	11,000,000	16,100,000	16,200,000	16,200,000	16,800,000	16,600,000	16,200,000	15,600,000	16,800,000	16,300,000	15,900,000	16,400,000	23,800,000
stock-based compensation expense	4,100,000	3,800,000		2,600,000	3,800,000	3,600,000		3,900,000	3,900,000	4,000,000		4,100,000	4,000,000	3,800,000		3,500,000	3,600,000	3,100,000		3,400,000	3,000,000	2,500,000		2,800,000	1,800,000	4,200,000		2,400,000	2,100,000	3,500,000		2,100,000	5,400,000	4,400,000		3,000,000	5,500,000	3,800,000		3,400,000	5,300,000	5,400,000
goodwill impairment								0																															-1,500,000
net income on asset dispositions																		100,000		1,100,000				0	300,000	200,000		700,000	-200,000	800,000
changes in operating assets and liabilities, net of acquisition:
accounts receivable	-3,000,000	25,100,000	300,000	-7,700,000	-7,400,000	8,200,000	9,000,000	11,100,000	-7,300,000	26,200,000	-18,700,000	900,000	8,800,000	-15,700,000	-300,000	-11,800,000	-900,000	2,200,000	11,500,000	-3,600,000	20,900,000	17,000,000	-8,700,000	-18,300,000	10,700,000	15,500,000	10,100,000	23,500,000	30,300,000	3,500,000	-10,200,000	-10,400,000	-2,800,000	8,100,000	-2,600,000	6,200,000	21,400,000	-16,600,000	-24,100,000	-500,000	26,100,000	7,500,000
inventories	-3,300,000	1,200,000		1,900,000	-3,100,000	-4,700,000		6,500,000	-4,500,000	-8,600,000		-18,700,000	-12,600,000	-4,500,000		700,000	5,900,000	2,800,000		-9,400,000	-20,600,000	-8,500,000		-6,900,000	-5,100,000	-8,200,000		-10,100,000	-6,200,000	-18,000,000		-4,300,000	-22,800,000	-900,000		11,500,000	8,500,000	-5,200,000	20,300,000	400,000	-31,000,000	-9,900,000
prepaid expenses and other assets	1,900,000	300,000	7,200,000	3,700,000	4,200,000	-200,000	-19,800,000	-200,000	1,900,000	-1,500,000	-500,000	2,900,000	500,000	100,000	-3,000,000	-200,000	800,000	500,000	1,000,000	-900,000	3,300,000	-2,000,000	1,900,000	-3,900,000	12,500,000	20,300,000	-8,800,000	-4,200,000	-34,100,000	1,400,000	-3,300,000	200,000	-500,000	1,300,000	-1,400,000	100,000	-100,000	3,100,000	-4,100,000	-4,600,000	1,400,000	1,300,000
accounts payable	4,800,000	-6,400,000	300,000			2,300,000	1,600,000	-14,200,000	6,100,000	-7,900,000	1,300,000	600,000	3,300,000	30,200,000	0	-9,700,000	4,000,000	-6,200,000	-10,800,000	-2,400,000	2,500,000	-8,200,000	-11,500,000	-7,500,000	-44,900,000	-19,700,000	7,500,000	-23,600,000	-68,000,000	20,100,000	16,600,000	-8,900,000	-100,000	11,200,000	2,400,000	-1,700,000	-13,600,000	19,400,000	-18,500,000	-13,200,000	9,900,000	36,500,000
accrued expenses	-7,200,000	-14,800,000	-7,700,000	7,000,000	16,900,000	-27,600,000	-8,000,000	17,400,000	-9,600,000	-27,500,000	11,400,000	10,200,000	-100,000	-28,600,000	57,800,000	-18,800,000	-3,600,000	-2,000,000	-51,600,000	6,700,000	-14,900,000	-14,500,000	24,900,000	19,700,000	-5,500,000	-23,800,000	-28,700,000	-71,100,000	46,800,000	-13,600,000	17,900,000	8,700,000	4,300,000	-19,600,000	23,200,000	2,300,000	5,900,000	2,600,000	22,800,000	11,900,000	-22,700,000	-26,500,000
deferred income taxes and other	-800,000	100,000	-42,200,000	600,000	2,600,000	-400,000	-19,900,000	-3,800,000	4,400,000	-3,100,000		400,000	100,000	-400,000	11,900,000	37,300,000	-46,700,000	-5,900,000	45,100,000	-23,800,000	-1,100,000	-6,400,000
cash from operating activities	6,800,000	25,700,000	57,900,000	23,000,000	27,800,000	-8,000,000	12,700,000	29,100,000	-2,600,000	-6,800,000	33,700,000	28,400,000	27,000,000	1,800,000	52,100,000	23,200,000	15,300,000	-3,300,000	1,100,000	1,100,000	1,100,000	-5,800,000	-2,900,000	-16,600,000	-31,900,000	-23,100,000	-7,400,000	-67,800,000	-96,700,000	26,300,000	64,100,000	23,400,000	19,700,000	37,000,000	44,900,000	49,900,000	51,500,000	42,500,000	23,000,000	18,900,000	16,000,000	39,700,000	40,600,000
investing activities
capital expenditures	-11,000,000	-6,700,000	-4,800,000	-3,000,000	-5,900,000	-4,100,000	-5,900,000	-3,900,000	-4,000,000	-4,000,000	-4,900,000	-5,300,000	-4,100,000	-5,000,000	-4,700,000	-4,800,000	-5,800,000	-5,700,000	-5,100,000	-3,000,000	-6,900,000	-5,200,000	-8,100,000	-7,100,000	-22,900,000	-12,500,000	-17,700,000	-10,700,000	-11,100,000	-9,600,000	-12,600,000	-14,000,000	-6,400,000	-10,200,000	-7,400,000	-7,600,000	-6,100,000	-8,000,000	-6,000,000	-19,200,000	-17,500,000	-27,700,000
free cash flows	-4,200,000	19,000,000	53,100,000	20,000,000	21,900,000	-12,100,000	6,800,000	25,200,000	-6,600,000	-10,800,000	28,800,000	23,100,000	22,900,000	-3,200,000	47,400,000	18,400,000	9,500,000	-9,000,000	-4,000,000	-1,900,000	-5,800,000	-11,000,000	-11,000,000	-23,700,000	-54,800,000	-35,600,000	-25,100,000	-78,500,000	-107,800,000	16,700,000	51,500,000	9,400,000	13,300,000	26,800,000	37,500,000	42,300,000	45,400,000	34,500,000	17,000,000	-300,000	-1,500,000	12,000,000
proceeds from rh divestiture post-closing settlement			0	0	0	2,100,000
investments in non-affiliates	-2,200,000	-2,400,000
cash from investing activities	-13,200,000	-9,100,000	-7,600,000	-12,000,000	-5,900,000	-2,000,000	81,000,000	-48,900,000	-6,500,000	-4,000,000		-4,700,000	-4,100,000	-121,700,000	-4,700,000	-4,800,000	-5,800,000	-5,700,000	-5,100,000	-7,000,000	-6,900,000	-5,200,000	-8,100,000	-57,600,000	-29,900,000	-12,500,000	-17,800,000	-56,500,000	723,400,000	-9,600,000	-12,600,000	-14,000,000	-6,300,000	-10,200,000	-4,200,000	-7,500,000	-181,200,000	-8,000,000	-6,000,000	-19,100,000	-17,500,000	-20,000,000	-10,300,000
financing activities
secured debt repayments	-2,400,000	-2,300,000	-2,300,000	-3,200,000	-1,500,000	-1,600,000	-1,600,000	0	-1,500,000	-1,600,000	-1,600,000	0
revolving credit facility proceeds			0	0	0	20,000,000	0				0	0
revolving credit facility repayments	0	-25,000,000	-25,000,000	-10,000,000	0	-10,000,000	-95,000,000	0	0	-20,000,000	-20,000,000	0				-40,000,000	-10,000,000	-5,000,000
purchases of treasury stock	-800,000	-2,200,000		-100,000	-3,500,000	-9,100,000		-9,200,000	-2,600,000	-1,100,000		-11,000,000	-14,700,000	-19,400,000		-100,000				-100,000				-100,000
proceeds from the exercise of stock options	0	400,000	0	600,000	0	500,000	-200,000	900,000	0	600,000	100,000	800,000	100,000	700,000	100,000	900,000	400,000	4,800,000	2,000,000	800,000			100,000	2,600,000	2,400,000	200,000	300,000	5,400,000	8,000,000	3,400,000		1,500,000	300,000	500,000						300,000
payment of contingent consideration liabilities			0	-3,300,000	0	-500,000													0
cash from financing activities	-3,200,000	-29,100,000	-27,400,000	-16,000,000	-5,000,000	-700,000	-114,700,000	46,700,000	-4,100,000	-22,100,000	-21,900,000	-10,200,000	-16,900,000	105,700,000	-25,800,000	-19,200,000	-10,100,000	-200,000	-68,300,000	-2,000,000			-100,000	2,500,000	800,000	-1,700,000	-1,600,000	5,400,000	-291,500,000	-36,700,000	1,900,000	1,500,000	-1,700,000	500,000	-10,700,000	-34,800,000			200,000	300,000	-50,100,000	-1,000,000	61,600,000
effect of exchange rate changes on cash and cash equivalents	2,900,000	1,800,000	-4,200,000	1,800,000	-500,000	-1,200,000	1,600,000	-1,600,000	-700,000	900,000	3,800,000	-3,000,000			-900,000	-1,300,000	400,000	-2,200,000	3,800,000	2,900,000	2,800,000	-6,600,000	2,000,000	-2,000,000	800,000	1,100,000	-500,000	-400,000	-7,200,000	3,400,000	200,000	400,000	0	2,100,000	-3,000,000	-100,000	-300,000	1,100,000	-200,000	-1,900,000	-300,000	-1,500,000	-1,300,000
increase in cash and cash equivalents			18,700,000	-3,200,000																			-9,100,000	-73,700,000			-27,300,000			-16,600,000	53,600,000	11,300,000	11,700,000	29,400,000				35,600,000	17,000,000	-1,800,000	-51,900,000	17,200,000	90,600,000
cash and cash equivalents - beginning of period	0	107,700,000		0	0	87,700,000		0	0	127,700,000		0	0	118,500,000		0	0	111,500,000		0	0	205,300,000		0	0	384,500,000		0	0	219,700,000		0	0	113,700,000		0	0	129,500,000		0	0	149,000,000
cash and cash equivalents - end of period	-6,700,000	97,000,000		-3,200,000	16,400,000	75,800,000		25,300,000	-13,900,000	95,700,000		10,500,000	2,200,000	104,300,000		-2,100,000	-200,000	100,100,000		-5,000,000	-2,700,000	187,700,000		-73,700,000	-60,200,000	348,300,000				203,100,000		11,300,000	11,700,000	143,100,000		7,500,000	-85,900,000	165,100,000		-1,800,000	-51,900,000	166,200,000
net income on asset dispositions and impairments		200,000		100,000	0	300,000										0
decrease in cash and cash equivalents		-10,700,000				-11,900,000		25,300,000	-13,900,000	-32,000,000		10,500,000	2,200,000	-14,200,000		-2,100,000	-200,000	-11,400,000		-5,000,000	-2,700,000	-17,600,000				-36,200,000										7,500,000
stock-based compensation
goodwill and intangibles impairment
loss on rh disposal
net incomees on asset dispositions and asset impairments
changes in operating assets and liabilities, net of acquisition
inventories, net of allowance
proceeds from the rh divestiture
acquisition of assets and businesses, net of cash acquired																							0
proceeds from issuance of secured debt											0	0	125,000,000	125,000,000
debt issuance costs
purchase of treasury stock																										-1,900,000	-300,000	0	-500,000	-100,000	-500,000	0			0	0			0	0
cash and cash equivalents - beginning of year
cash and cash equivalents - end of year
supplemental cash flow disclosure:
cash paid (refunded) for income taxes
cash paid for interest
supplemental noncash disclosure
capital expenditures included in accounts payable or accrued expenses
acquisition of assets and investments in businesses								-45,000,000				600,000	0	-116,700,000
investment in note receivable
payments of debt issuance costs												0	-2,300,000	-600,000
acquisition of minority interest investment
cash (used in) investing activities
cash refund for income taxes
income tax receivable
senior secured revolving credit facility proceeds														20,000,000
senior secured revolving credit facility repayments														-20,000,000
asset impairments
net incomees on asset dispositions																																											3,200,000
debt repayments																							0	0			0	0	-299,000,000	-40,000,000									0	0	-50,000,000	-1,000,000	-10,900,000
line of credit facility proceeds																																			0	0
line of credit facility repayments																																			-10,000,000	-35,000,000
cash (refund) paid for income taxes
changes in operating assets and liabilities:
net non-cash gain on divestiture																											0	0
proceeds from the divestiture																											0	19,800,000
cash paid for income taxes
proceeds from dispositions of property																															0	0
other																								300,000	-2,200,000	300,000		1,500,000	-12,100,000	600,000		3,200,000	2,900,000	3,500,000		-200,000	500,000	5,500,000		-2,000,000	800,000	-600,000	-300,000
acquisition of business, net of cash acquired																											-100,000								0	100,000
increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash - end of period
net incomees (gains) on asset dispositions
proceeds from the exercise of stock options and other
asset impairment
debt proceeds																																											636,100,000
proceeds and excess tax benefits from the exercise of stock options
spin-off cash distribution to kimberly-clark
net transfers from kimberly-clark
net gain on asset dispositions																																				3,000,000	700,000	100,000
share-based compensation
net (gains) losses on asset dispositions
cash outflows for acquisitions
net transfers from (to) kimberly-clark
net (gain) loss on asset dispositions																																								2,200,000	2,300,000	-12,100,000
proceeds from property dispositions																																								100,000	0	7,700,000
change in kimberly-clark's net investment
benefit from losses on accounts receivable and inventories																																											2,700,000
deferred income taxes																																											-21,100,000
amortization of debt issue costs and debt discount
deposit received on pending sale of assets
share-based compensation charged by kimberly-clark
changes in operating working capital:
decrease (increase) in accounts receivable
increase in inventories
increase in trade accounts payable
decrease in accrued expenses
decrease in accrued income taxes
capital spending
cash outflows for acquisitions and investments

We provide you with 20 years of cash flow statements for Avanos Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Avanos Medical stock. Explore the full financial landscape of Avanos Medical stock with our expertly curated income statements.

The information provided in this report about Avanos Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.